Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Twist Bioscience has a “Moderate Buy” consensus from 10 analysts: eight rate it a buy, one a hold and one a sell. The average 12-month price target is $98.30.
• The company reported quarterly revenue of $118.38 million, exceeding estimates of $114.55 million, while its adjusted loss of $0.56 per share was wider than the expected $0.51 loss. Revenue increased 23.2% year over year.
• Twist shares opened at $141.38, near their 52-week high of $155.44, after rising substantially above their 50-day and 200-day moving averages. Insiders sold 193,099 shares worth approximately $24.0 million over the past three months.

Shares of Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $98.30.

TWST has been the subject of a number of research reports. TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a report on Monday, August 3rd. Piper Sandler increased their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an "overweight" rating in a report on Wednesday, August 5th. Leerink Partners set a $110.00 price target on shares of Twist Bioscience in a research report on Thursday, July 16th. Canaccord Genuity Group lifted their price objective on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a report on Wednesday, June 24th.

Insider Buying and Selling at Twist Bioscience

In related news, insider Dennis Cho sold 14,205 shares of the business's stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the completion of the transaction, the insider directly owned 105,141 shares in the company, valued at $9,436,404.75. The trade was a 11.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 291 shares of the company's stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the sale, the senior vice president directly owned 120,414 shares in the company, valued at approximately $10,514,550.48. The trade was a 0.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 193,099 shares of company stock worth $24,026,581. 3.08% of the stock is currently owned by company insiders.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new position in Twist Bioscience in the third quarter valued at approximately $28,000. Western Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the 1st quarter worth approximately $31,000. Strs Ohio acquired a new stake in shares of Twist Bioscience during the 1st quarter worth approximately $33,000. Strategic Advocates LLC increased its holdings in shares of Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company's stock valued at $34,000 after purchasing an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its holdings in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company's stock valued at $44,000 after purchasing an additional 571 shares in the last quarter.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $141.38 on Monday. The firm has a market capitalization of $8.87 billion, a price-to-earnings ratio of -63.68 and a beta of 2.14. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The business has a fifty day moving average of $106.95 and a 200 day moving average of $74.01. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $155.44.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business's revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.33 EPS. As a group, research analysts expect that Twist Bioscience will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source